Logo EURACAN - European Network For Rare Adult Solid Cancer Logo European Reference Network TO ALL EURACAN GUIDELINES
Welcome to the EURACAN’s Clinical Practice Guidelines
Click to open the video

Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up



Fassnacht M, Assie G, Baudin E, Eisenhofer G, de la Fouchardiere C, Haak HR, de Krijger R, Porpiglia F, Terzolo M, Berruti A; ESMO Guidelines Committee. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Aug 27:S0923-7534(20)42107-6. doi: 10.1016/j.annonc.2020.08.2099. Epub ahead of print. PMID: 32861807.


M. Fassnacht1,2, G. Assie3,4, E. Baudin5, G. Eisenhofer6, C. de la Fouchardiere7, H. R. Haak8,9,10, R. de Krijger11,12, F. Porpiglia13,14, M. Terzolo15 & A. Berruti16, on behalf of the ESMO Guidelines Committee*

1Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of Würzburg, Würzburg;
2Comprehensive Cancer Center Mainfranken, University of Würzburg, Würzburg, Germany;
3Department of Endocrinology, Reference Center for Rare Adrenal Diseases, Reference Centre for Rare Adrenal Cancers, Hôpital Cochin, Assistance Publique Hôpitaux de Paris, Paris;
4Institut Cochin, Institut National de la Santé et de la Recherche Médicale U1016, Centre National de la Recherche Scientifique UMR8104, Université Paris Descartes, Sorbonne Paris Cité, Paris;
5Department of Endocrine Oncology and Nuclear Medicine, Gustave Roussy, Villejuif, France;
6Department of Medicine III and Institute of Clinical Chemistry and Laboratory Medicine, Technische Universität Dresden, Dresden, Germany;
7Department of Medical Oncology, Centre Léon Bérard, University Claude Bernard Lyon I, Lyon, France;
8Department of Internal Medicine Máxima Medisch Centrum, Eindhoven;
9Department of Internal Medicine, Division of General Internal Medicine, Maastricht University Medical Centre, Maastricht;
10Maastricht University, CAPHRI School for Public Health and Primary Care, Ageing and Long-Term Care, Maastricht;
11Department of Pathology, University Medical Center Utrecht, Utrecht;
12Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands;
13Division of Urology, San Luigi Hospital – Orbassano, Turin;
14Department of Oncology, University of Turin, Turin;
15Internal Medicine, Department of Clinical and Biological Sciences, San Luigi Hospital, University of Turin, Turin;
16Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia, ASST-Spedali Civili, Brescia, Italy.

*Correspondence to: ESMO Guidelines Committee, ESMO Head Office, Via Ginevra 4, 6900 Lugano, Switzerland. E-mail: clinicalguidelines@esmo.org
†Approved by the ESMO Guidelines Committee: June 2020. This publication supersedes the previously published version—Ann Oncol 2012; 23 (Suppl 7): vii131–vii138.


Patient’s typology